ABSTRACT
BACKGROUND: Genetics play an important role in several medical domains; however, the influence of human leukocyte antigen (HLA) genotype on the development of periprosthetic joint infection (PJI) in total hip arthroplasty (THA) remains unknown. The primary aim of this study was to determine if HLA genotype is associated with the development of bacterial PJI in THA. Secondarily, we evaluated the association between HLA genotype and PJI treatment success. METHODS: A retrospective, matched, case-control study was performed using prospectively collected data from a single institution. A total of 49 patients who underwent primary THA were included, with a mean follow-up of 8.5 years (range, 4.2 to 12.9). The 23 cases (PJI) and 26 controls (no PJI) were matched for age, sex, follow-up, body mass index, primary diagnosis, and comorbidities (P > .05). High-resolution genetic analysis targeting 11 separate HLA loci was performed in all patients using serum samples. The HLA gene frequencies and carriage rates were determined and compared between cohorts. A subgroup analysis of PJI treatment success (18) and failure (5) was performed. Statistical significance was set at P = .10 for genetic analysis and at 0.05 for all other analyses. RESULTS: There were 4 HLA alleles that were significantly associated with the development of PJI. The 3 at-risk alleles included HLA-C∗06:02 (odds ratio 5.25, 95% CI [confidence interval] 0.96 to 28.6, P = .064), HLA-DQA1∗04:01 (P = .096), and HLA-DQB1∗04:02 (P = .096). The single protective allele was HLA-C∗03:04 (odds ratio 0.12, 95% CI 0.01 to 1.10, P = .052). There were no specific HLA alleles that were associated with treatment success or failure. CONCLUSIONS: This study suggests that there are at-risk and protective HLA alleles associated with the development of PJI in THA. To our knowledge, this is the first study to demonstrate an association between patient HLA genotype and the development of PJI. A larger study of the subject matter is necessary and warranted.
ABSTRACT
BACKGROUND: Concerns remain that thinner highly crosslinked polyethylene (HXLPE) liners in modern total hip arthroplasty (THA) may lead to premature liner-related failures or revision. The aim of this study was to evaluate the effect of liner thickness on survival and revision rates of HXLPE in primary THA after more than 10 years. METHODS: We retrospectively identified 2,565 primary THAs using HXLPE with a mean follow-up of 13 years (range, 11 to 19). Patients were grouped for each mm of polyethylene thickness. Liner thickness varied from 4.9 to 12.7 mm, with one third measuring less than 6 mm. Primary outcomes were reoperation, all-cause revision, and liner-related revision. RESULTS: The reoperation rate was 7.3%, the all-cause revision rate was 5.6%, and the liner-related revision rate was 0.04%. There was no significant difference in all-cause revision when stratified by liner thickness (P = .286) and liner thickness was not associated with liner-related revision (n = 1). There was a statistically, but not clinically significant difference in mean liner thickness for the cohort that underwent reoperation (7.09 versus 6.89 mm, P = .01) and all-cause revision (7.16 versus 6.89 mm, P = .031). CONCLUSION: In our cohort, liner thickness was not associated with all-cause revision-free survival, and there was no clinically significant difference in liner thickness between those patients who did require a reoperation or all-cause revision, and those who did not. There was only 1 liner-related failure in the entire cohort. Our results indicate that using thinner HXLPE liners to maximize femoral head size in THA is a safe practice that does not lead to increased revision rates or liner failure at a mean 13-year follow-up.
